Krystal BiotechFRA:4KB +2.29%58 EBITDA Margin % is 47.62% as of Mar. 2026, which is 26% above its 10-year median of 37.85. GuruFocus rates FRA:4KB with a GF Score™ of 58/100 and a GF Value™ of €263.13 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 944 Biotechnology companies, Krystal Biotech ranks better than 93.01% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Krystal Biotech's EBITDA for the
three
months ended in Mar. 2026 was €47.9 Mil. Krystal Biotech's Revenue for the
three
months ended in Mar. 2026 was €100.6 Mil. Therefore, Krystal Biotech's EBITDA margin for the quarter that ended in Mar. 2026 was 47.62%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Krystal Biotech EBITDA Margin % Related Terms
Krystal Biotech EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Krystal Biotech's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4KB vs NUVL, PRAX, TECH: EBITDA Margin % Comparison
For the Biotechnology subindustry, Krystal Biotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krystal Biotech EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Krystal Biotech's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Krystal Biotech's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krystal Biotech (FRA:4KB) has a EBITDA Margin % of 47.62% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Krystal Biotech and its competitors. This is 26% above median its historical median of 37.85. According to the industry distribution chart, Krystal Biotech ranks #66 out of 944 companies in the Biotechnology industry, placing it in the top 7%.
Is Krystal Biotech's EBITDA Margin % too high?
Krystal Biotech's current EBITDA Margin % of 47.62% is 26% above median its 10-year median of 37.85. Based on the distribution chart, Krystal Biotech ranks #66 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Krystal Biotech has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's EBITDA Margin % compare to NUVL and PRAX?
According to the Biotechnology industry distribution chart, Krystal Biotech ranks #66 out of 944 companies for EBITDA Margin %. This places Krystal Biotech in the top 7% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Krystal Biotech and its competitors. Krystal Biotech's current EBITDA Margin % is 47.62%, which is 26% above median its own 10-year median of 37.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Based on GuruFocus' analysis, Krystal Biotech (FRA:4KB) is currently considered Modestly Overvalued. The stock's GF Value™ is €263.13, compared to a current price of €303.60 — trading 15.4% above its estimated fair value. The current EBITDA Margin % is 47.62%, which is 26% above median its 10-year median of 37.85. Krystal Biotech's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Krystal Biotech (FRA:4KB), the current EBITDA Margin % is 47.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krystal Biotech (FRA:4KB) Overvalued in 2026?
Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued.
The current stock price of €303.60 is trading 15.4% above its estimated GF Value™ of €263.13.
GuruFocus considers Krystal Biotech to be Modestly Overvalued.
Key valuation signals for FRA:4KB:
EBITDA Margin %: 47.62% (26% above median its 10-year median of 37.85)
GF Value™: €263.13 vs. price of €303.60 (15.4% above fair value)
No single metric tells the full story. See the FRA:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
58GF Score
Get the complete analysis for FRA:4KB
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4KB has been successfully added to your 
